Dublin, Ireland (PRWEB) December 23, 2013
Dignity Sciences Ltd, a privately held biopharmaceutical company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application serial number 13/906,673, entitled "Cosmetic Compositions Comprising EPA and Salicylic Acid and Methods of Making and Using Same." The application has allowed claims that provide Dignity Sciences exclusivity for topical compositions of its advanced over the counter (OTC) product line DS100SA and DS101SA. In addition, the allowed claims provide exclusivity for methods of using these compositions to ameliorate a variety of skin conditions including, but not limited to, acne and wrinkles. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The granted patent will provide DS100SA and DS101SA exclusivity until at least 2033.
Since its foundation in 2010, Dignity Sciences research and development has grown its patent portfolio to include the Company’s lead pharmaceutical compound DS107E, pharmaceutical product enhancements, the next generation pharmaceutical compositions and OTC products. The Company believes its product portfolio of prescription and OTC semi-synthetic fatty acids to be the best in class.
About DS100SA and DS101SA
DS100SA and DS101SA contain novel combinations of Dignity Sciences’ high purity bioactive semi-synthetic fatty acids and salicylic acid.
About Dignity Sciences
Dignity Sciences, a privately held biopharmaceutical company, was established to discover and develop scientifically innovative healthcare solutions that improve the quality of life of people with diseases for which current therapies are unsatisfactory. Dignity Sciences is led by recognized experts in developing omega-6 fatty acids, including their bioactive derivatives, for the treatment of human disease.